Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (PFE) announced positive Phase 3 BREAKWATER trial results for BRAFTOVI® combination therapy in treating BRAF V600E-mutant metastatic colorectal cancer (mCRC). The trial showed a significantly higher objective response rate of 60.9% compared to 40% with standard chemotherapy.
Key findings include a median duration of response of 13.9 months for the BRAFTOVI combination versus 11.1 months for chemotherapy. Additionally, 22.4% of BRAFTOVI-treated patients maintained response for 12+ months, compared to 11.4% in the chemotherapy group.
While overall survival data is not yet mature, early trends favor the BRAFTOVI combination. The safety profile aligned with known profiles of individual components, with serious treatment-emergent adverse events occurring in 37.7% of BRAFTOVI combination patients versus 34.6% in the chemotherapy group. The FDA granted accelerated approval for this treatment in December 2024.
Pfizer (PFE) announced positive topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, combined with BCG therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint, showing significant improvement in event-free survival compared to BCG alone.
The treatment could potentially be the first PD-1 inhibitor approved in combination with BCG for this indication, representing the first major advancement in BCG-naïve, high-risk NMIBC treatment in over 30 years. Approximately 100,000 people globally are diagnosed with high-risk NMIBC annually, with 40-50% experiencing recurrent disease.
The safety profile of sasanlimab with BCG was consistent with known profiles of both treatments. Pfizer plans to submit the results to regulatory authorities and present them at upcoming medical conferences.
Pfizer Inc. (NYSE: PFE) has announced a public webcast featuring a discussion with Albert Bourla, Chairman and CEO, at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. PST.
The webcast will be accessible through www.pfizer.com/investors, with registration details available immediately. A transcript and replay will be posted within 24 hours and remain accessible for at least 90 days.
Pfizer, with a 175-year legacy, focuses on developing breakthrough therapies and vaccines that improve lives globally. The company emphasizes quality, safety, and value in healthcare product development, working across developed and emerging markets to advance wellness and treatments for major diseases. They collaborate with healthcare providers, governments, and communities to expand access to affordable healthcare worldwide.
Stuart Therapeutics has appointed Tracy Valorie and Jason Werner to its Board of Directors, expanding it to five members. They replace Robert O. Baratta, MD, who passed away in Q3, and Diane Black, RN, who resigned. Valorie, owner of TMV Associates , brings 30 years of pharmaceutical and biotech experience, including senior roles at Bausch + Lomb and Pfizer. Werner serves as Executive Chairman of Sightstream Biotherapeutics and has extensive experience in ophthalmology, including co-founding Eyevance Pharmaceuticals. Both appointments strengthen Stuart's leadership as it advances in ophthalmology therapeutics development and commercialization.
Pfizer (PFE) has received FDA accelerated approval for BRAFTOVI® combination with cetuximab and mFOLFOX6 as the first-line treatment for metastatic colorectal cancer with BRAF V600E mutation. The approval is based on the Phase 3 BREAKWATER trial results, which showed a 61% overall response rate compared to 40% in the control arm. The median duration of response was 13.9 months versus 11.1 months for the control group.
This marks the first and only combination regimen with targeted therapy approved for first-line use in this patient population. The safety profile was consistent with known profiles of each agent, with common adverse reactions including peripheral neuropathy, nausea, and fatigue. The approval was granted under FDA's Project FrontRunner initiative.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for 10:30 a.m. EST on Tuesday, February 4, 2025. The call will discuss Pfizer's Fourth Quarter and Full Year 2024 Performance Report, which will be released that morning.
Investors and the public can access the webcast through www.pfizer.com/investors. Participants can join via webcast or by phone using the following numbers: 800-456-4352 (US/Canada) or 785-424-1086 (International), with passcode '30674'. The webcast replay and transcript will be available within 24 hours after the call and accessible for at least 90 days on Pfizer's investor website.
Grindr announced that its Roam feature, which allows users to explore and connect with locals worldwide, will be available for free during a 12-day holiday period from December 22 to January 2 in the U.S., sponsored by ViiV Healthcare. Typically priced at $5.99 per hour, Roam enables users to have their profiles appear on local grids in different cities or countries, facilitating connections for travel planning, relocation, or virtual exploration. The feature, launched earlier this year, has already helped thousands of users connect with locals before visiting new destinations.
Pfizer (PFE) has provided its full-year 2025 guidance, projecting revenue between $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company expects operational revenue growth of flat to 5% compared to 2024, with adjusted diluted EPS operational growth of 10% to 18%.
The company has achieved its goal of $4.0 billion in net cost savings through 2024 and anticipates an additional $500 million in savings in 2025. The guidance considers a $1 billion unfavorable impact from the Inflation Reduction Act Part D Redesign changes. Pfizer's 2025 adjusted expenses are projected at $13.3 to $14.3 billion for SI&A and $10.7 to $11.7 billion for R&D.
Pfizer (NYSE: PFE) has announced an increase in its quarterly cash dividend to $0.43 per share for the first quarter of 2025. The dividend will be paid on March 7, 2025, to shareholders of record as of January 24, 2025. This marks Pfizer's 345th consecutive quarterly dividend payment, demonstrating the company's commitment to shareholder returns. Chairman and CEO Dr. Albert Bourla emphasized that this dividend increase reflects Pfizer's strong financial performance and disciplined execution.
Pfizer (PFE) and Alliance Foundation Trials announced significant results from the Phase 3 PATINA trial for IBRANCE® in treating HR+, HER2+ metastatic breast cancer. The trial demonstrated that adding IBRANCE to standard first-line maintenance therapy significantly improved progression-free survival (PFS). Patients treated with IBRANCE combination therapy achieved a median PFS of 44.3 months compared to 29.1 months for those on standard therapy alone, representing a 15-month improvement.
The safety profile aligned with previous known data, with common adverse events including neutropenia, leukopenia, fatigue, stomatitis, and diarrhea. IBRANCE, approved since 2015, has been prescribed to over 773,000 patients and is approved in more than 108 countries. Pfizer plans to present these findings to regulatory authorities.